Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular dis ...

Collaboration leverages Variant Bio's innovative VB-Inference Platform and expertise partnering with global ...

Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 725 from DKK 975 and keeps a Hold rating on the shares.Don't Miss Our ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage ...